Implementing Toxicity Testing in the 21st Century (TT21C): Making safety decisions using toxicity pathways, and progress in a prototype risk assessment

Abstract

Risk assessment methodologies in toxicology have remained largely unchanged for decades. The default approach uses high dose animal studies, together with human exposure estimates, and conservative assessment (uncertainty) factors or linear extrapolations to determine whether a specific chemical exposure is 'safe' or 'unsafe'. Although some incremental changes have appeared over the years, results from all new approaches are still judged against this process of extrapolating high-dose effects in animals to low-dose exposures in humans. The US National Research Council blueprint for change, entitled Toxicity Testing in the 21st Century: A Vision and Strategy called for a transformation of toxicity testing from a system based on high-dose studies in laboratory animals to one founded primarily on in vitro methods that evaluate changes in normal cellular signalling pathways using human-relevant cells or tissues. More recently, this concept of pathways-based approaches to risk assessment has been expanded by the description of 'Adverse Outcome Pathways' (AOPs). The question, however, has been how to translate this AOP/TT21C vision into the practical tools that will be useful to those expected to make safety decisions. We have sought to provide a practical example of how the TT21C vision can be implemented to facilitate a safety assessment for a commercial chemical without the use of animal testing. To this end, the key elements of the TT21C vision have been broken down to a set of actions that can be brought together to achieve such a safety assessment. Such components of a pathways-based risk assessment have been widely discussed, however to-date, no worked examples of the entire risk assessment process exist. In order to begin to test the process, we have taken the approach of examining a prototype toxicity pathway (DNA damage responses mediated by the p53 network) and constructing a strategy for the development of a pathway based risk assessment for a specific chemical in a case study mode. This contribution represents a 'work-in-progress' and is meant to both highlight concepts that are well-developed and identify aspects of the overall process which require additional development. To guide our understanding of what a pathways-based risk assessment could look like in practice, we chose to work on a case study chemical (quercetin) with a defined human exposure and to bring a multidisciplinary team of chemists, biologists, modellers and risk assessors to work together towards a safety assessment. Our goal was to see if the in vitro dose response for quercetin could be sufficiently understood to construct a TT21C risk assessment without recourse to rodent carcinogenicity study data. The data presented include high throughput pathway biomarkers (p-H2AX, p-ATM, p-ATR, p-Chk2, p53, p-p53, MDM2 and Wip1) and markers of cell-cycle, apoptosis and micronuclei formation, plus gene transcription in HT1080 cells. Eighteen point dose response curves were generated using flow cytometry and imaging to determine the concentrations...

Real-time monitoring of oxygen uptake in hepatic bioreactor shows CYP450-independent mitochondrial toxicity of acetaminophen and amiodarone

“…3a, b). The dynamics of the response reveals important information on the drug mechanism of action (Adeleye et al 2014;Vinken 2013) and the presence of short-lived subthreshold…”

“…However, these end-point methods provide little information on the kinetics of the biological response. This is a fundamental drawback of animal studies, as only time-resolved analysis can provide mechanistic information, termed mode of action, necessary to extrapolate the toxic effect on other organs (Adeleye et al 2014;Gocht et al 2014;Vinken 2013).…”

Real-time monitoring of metabolic function in liver-on-chip microdevices tracks the dynamics of mitochondrial dysfunction

“…Using a lung-on-chip device, Huh et al (1) demonstrated that mechanical forces are critical for the development of nanoparticle toxicity in lung tissue, while our group and others demonstrated the long-term maintenance of hepatocyte function in a microfluidic bioreactor (2)(3)(4)(5). Regretfully, most organ-on-chip devices still rely on endpoint assays to assess drug toxicity, providing limited dynamic information that can be used to assess the compound mechanism of action (6,7).…”

Evidence-based absorption, distribution, metabolism, excretion (ADME) and its interplay with alternative toxicity methods

“…Many studies are highly theoretical, but they may hold a lot of promise to identify signatures (SoT) and pathways of toxicity (PoT) (Adeleye et al, 2015;Kleensang et al, 2014). Network research has three primary goals.…”